Dr. Rebecca C. Arend
Claim this profileUniversity of Alabama at Birmingham Cancer Center
Area of expertise
Ovarian Cancer
Rebecca C. Arend has run 8 trials for Ovarian Cancer. Some of their research focus areas include:
Cancer
Rebecca C. Arend has run 6 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Alabama At Birmingham Cancer Center
University Of Alabama At Birmingham
Clinical Trials Rebecca C. Arend is currently running
Carboplatin + Mirvetuximab
for Ovarian Cancer
The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα receptor over-expression via a centralized immunohistochemical assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients will receive NACT with one cycle of carboplatin, followed by mirvetuximab + carboplatin (if FRα +) every 21 days for three cycles prior to interval cytoreductive surgery (iCRS). A total of 70 will be included in the study. Following completion of 4 cycles total of NACT and after allowing for appropriate recovery of cycle # 4, patients eligible for surgery, will undergo an iCRS. Patients will then complete 3 more cycles of mirvetuximab + carboplatin for a total of 7 intended cycles of treatment. It is up to the treating physician if they want to add bevacizumab to the last 2 cycles or use any type of maintenance therapy. The decision to add bevacizumab or use maintenance therapy does not need to be made upfront. Patients will sign a screening consent form prior to tissue biopsy. If a patient is found to be FRα negative, their treating physician can select the treatment they deem appropriate and the patient will be declared a screen failure. Patients with BRCA mutations are not excluded from this trial and are allowed to receive standard of care maintenance therapy including bevacizumab and/or PARP inhibitors.
Recruiting
1 award
Phase 2
9 criteria
pBI-11 Vaccine
for Human Papillomavirus Infection
This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human papillomavirus (HPV18+) cervical infection. The DNA vaccine is designed to promote an immune response to treat disease caused by HPV types 16 and 18, viruses that can cause cervical cancer. The pBI-11 DNA vaccine or a placebo will be administered intramuscularly using the TriGridTM Delivery System.
Recruiting
0 awards
Phase 2
4 criteria
More about Rebecca C. Arend
Clinical Trial Related
3 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Rebecca C. Arend has experience with
- Paclitaxel
- Binimetinib
- Olaparib
- Palbociclib
- Ipatasertib
- Selumetinib Sulfate
Breakdown of trials Rebecca C. Arend has run
Ovarian Cancer
Cancer
Endometrial Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rebecca C. Arend specialize in?
Rebecca C. Arend focuses on Ovarian Cancer and Cancer. In particular, much of their work with Ovarian Cancer has involved KRAS positive patients, or patients who are Stage IV.
Is Rebecca C. Arend currently recruiting for clinical trials?
Yes, Rebecca C. Arend is currently recruiting for 5 clinical trials in Birmingham Alabama. If you're interested in participating, you should apply.
Are there any treatments that Rebecca C. Arend has studied deeply?
Yes, Rebecca C. Arend has studied treatments such as Paclitaxel, Binimetinib, Olaparib.
What is the best way to schedule an appointment with Rebecca C. Arend?
Apply for one of the trials that Rebecca C. Arend is conducting.
What is the office address of Rebecca C. Arend?
The office of Rebecca C. Arend is located at: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama 35233 United States. This is the address for their practice at the University of Alabama at Birmingham Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.